NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Generic: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
ScieGen PharmaceuticalsManufacturer
ORALRoute
NAPROXENActive Substance
2023-10-11Original Approval
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM is FDA application ANDA217738, sponsored by SCIEGEN PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
NAUSEA
4 reports
2
OFF LABEL USE
3 reports
3
ARRHYTHMIA
2 reports
4
ASTHENIA
2 reports
5
BLOOD PRESSURE INCREASED
2 reports
6
COUGH
2 reports
7
GASTROINTESTINAL DISORDER
2 reports
8
HYPERHIDROSIS
2 reports
9
INTERSTITIAL LUNG DISEASE
2 reports
10
NIGHTMARE
2 reports